# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Gwen Ifill (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML032-SYN
- Date: 2026-01-20
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lorna Achebe-Price, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Endometrial biopsy result and gynecologic oncology consultation. **S**

## History of present illness

Ms. Ifill returns two weeks after her first visit. The transvaginal ultrasound two days after that visit showed a 16 mm heterogeneous endometrium with internal blood flow and two small fibroids. The endometrial biopsy taken at the first visit, telephoned to her four days later, shows endometrioid adenocarcinoma, FIGO grade 2, with loss of MLH1 and PMS2 staining and a wild-type p53 pattern. CT of the chest, abdomen and pelvis the next week showed an enlarged right external iliac lymph node and an enlarged left para-aortic node, with no disease in the liver, lungs, bones or peritoneum. Dr. Delacroix of gynecologic oncology saw her this morning. The bleeding has lessened to occasional spotting. She has no pain, bowel or bladder change, leg swelling or weight loss. She says she is shaken but glad the answer came quickly, and wants to keep working through treatment if she can. She has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Biopsy | Endometrioid adenocarcinoma, FIGO grade 2; MLH1 and PMS2 lost; p53 wild-type |
| Imaging | Ultrasound: endometrium 16 mm, heterogeneous. CT: enlarged right external iliac and left para-aortic nodes; no distant disease |
| Symptoms | Spotting only; no pain |
| Coordination | Gynecologic oncology seen today; surgery in two weeks |
| Her questions | Whether the nodes mean the cancer has spread, whether it is inherited, and whether she can keep working |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever, night sweats or weight loss |
| Genitourinary | Positive | Occasional spotting; no urinary symptoms |
| Gastrointestinal | Negative | No abdominal pain or change in bowel habit |
| Respiratory | Negative | No cough or breathlessness |
| Cardiovascular | Negative | No leg swelling or calf pain |
| Psychiatric | Positive | Worried and sleeping less; PHQ-9 6 and GAD-7 7; no thoughts of self-harm |

6 systems reviewed. **S**

## Current medications

- No current medications. **S**

## Allergies

- No known allergy **S**

## Objective

BP 132/82 mmHg; pulse 84 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 74.2 kg; BMI 27.3 kg/m². All vital signs are synthetic.

Hemoglobin: 12.1 g/dL; White cell count: 6 10*3/uL; Absolute neutrophil count: 3.6 10*3/uL; Platelets: 274 10*3/uL; Sodium: 139 mmol/L; Potassium: 4.3 mmol/L; Creatinine: 0.8 mg/dL; eGFR (CKD-EPI 2021): 84 mL/min/1.73 m²; ALT: 19 U/L; AST: 21 U/L; Total bilirubin: 0.5 mg/dL; Albumin: 4.1 g/dL; CA-125: 28 U/mL; PHQ-9: 6; GAD-7: 7. All results are synthetic.

## Change since baseline

- Hemoglobin: 11.8 g/dL (low) at baseline, 12.1 g/dL at this visit **S**
- White cell count: 6.2 10*3/uL at baseline, 6 10*3/uL at this visit **S**
- Platelets: 268 10*3/uL at baseline, 274 10*3/uL at this visit **S**
- Creatinine: 0.82 mg/dL at baseline, 0.8 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 82 mL/min/1.73 m² at baseline, 84 mL/min/1.73 m² at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 74.2 kg; blood pressure 132/82, pulse 84 |
| Abdomen | Soft, non-tender; no mass or fluid |
| Pelvic | Examined with Dr. Delacroix and a chaperone: small amount of blood at the cervical os; cervix normal; uterus mobile, slightly enlarged; no adnexal mass or parametrial thickening |
| Lymph nodes | No inguinal or supraclavicular nodes |
| Extremities | No leg swelling |
| Psychiatric | Composed, direct and focused; anxious when talking about the nodes |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Endometrioid adenocarcinoma of the endometrium, FIGO grade 2, mismatch repair deficient** (C54.1). Endometrial cancer diagnosed four days after her first visit, because the bleeding was sampled at once and the ultrasound was done the same week. The enlarged pelvic and para-aortic nodes on CT suggest stage III disease, which surgery will settle. Dr. Delacroix recommends minimally invasive hysterectomy with removal of both tubes and ovaries, sentinel node mapping and removal of the enlarged nodes in two weeks; treatment after surgery will depend on the final stage and the molecular class. The loss of MLH1 and PMS2 is the universal Lynch syndrome screen; MLH1 promoter methylation testing has been sent on the biopsy to tell an acquired change from an inherited one. CA-125 28 U/mL is normal and will not be used for follow-up. Fit for surgery: albumin 4.1 g/dL, creatinine 0.80 mg/dL. **S**
   - Surgery with Dr. Delacroix in two weeks.
   - MLH1 promoter methylation on the biopsy; POLE sequencing on the surgical specimen.
   - Hepatitis B, hepatitis C and HIV tests drawn today, in case systemic treatment follows.
   - Genetic counseling once the methylation result is back.
2. **Postmenopausal bleeding** (N95.0). Explained by the diagnosis made today; superseded. **S**
   - Problem resolved.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Evaluation of any postmenopausal bleeding | At the first report | Up to date | Examined and sampled at the first visit, without a waiting period |
| Laboratory | Endometrial tissue sampling | At the first evaluation of postmenopausal bleeding, with transvaginal ultrasound | Up to date | Office biopsy at the first visit: endometrioid adenocarcinoma, FIGO grade 2 |
| Imaging | Transvaginal ultrasound | At the first evaluation, together with sampling | Up to date | Endometrium 16 mm, heterogeneous, with blood flow; two small intramural fibroids |
| Imaging | CT of the chest, abdomen and pelvis | Before primary treatment when high-grade or extrauterine disease is suspected | Up to date | Enlarged right external iliac and left para-aortic nodes; no distant disease |
| Laboratory | Mismatch repair immunohistochemistry (universal Lynch syndrome tumor screen) | At diagnosis, on every endometrial cancer | Up to date | Loss of MLH1 and PMS2; MSH2 and MSH6 retained |
| Laboratory | MLH1 promoter methylation | Reflex when MLH1 is lost | Ordered | Sent on the biopsy today |
| Laboratory | p53 immunohistochemistry and POLE sequencing (molecular classification) | At diagnosis or on the surgical specimen | Ordered | p53 wild-type pattern on the biopsy; POLE to be sequenced on the surgical specimen |
| Laboratory | CA-125 | At diagnosis; afterwards only if raised at diagnosis | Completed today | 28 U/mL, normal; not to be repeated routinely |
| Laboratory | Blood count, chemistry and liver tests before surgery | Within 30 days before surgery | Completed today | Hemoglobin 12.1 g/dL, white cells 6.0, neutrophils 3.6, platelets 274; sodium 139, potassium 4.3, creatinine 0.80 mg/dL, eGFR 84; ALT 19, AST 21, bilirubin 0.5, albumin 4.1 |
| Laboratory | Hepatitis B, hepatitis C and HIV screening | Before systemic cancer treatment | Ordered | Hepatitis B surface antigen, core antibody and surface antibody, hepatitis C antibody, and HIV drawn today |
| Referral | Gynecologic oncology | Before any surgery for endometrial cancer | Completed today | Seen this morning; recommendations in the consultation note |
| Referral | Genetic counseling | At diagnosis when the tumor screen is abnormal | Due | After the methylation result, at the next visit |
| Survey | Distress and depression screen (PHQ-9) | At diagnosis, each treatment phase, and when symptoms change | Completed today | PHQ-9 6 and GAD-7 7, mild, with worry about the diagnosis; no thoughts of self-harm |
| Self-management | Information, support and privacy | At diagnosis and throughout | Completed today | Plain explanation with written information; she chose who would be told and asked that notes go only to her clinicians |

## Goal progress

- Endometrial tissue diagnosis and ultrasound within one week, and a gynecologic oncology plan within three weeks of presentation. Outcome by 2026-01-20: Biopsy at the first visit, ultrasound in two days, result in four days, CT in eight, consultation at two weeks. **S**
- Surgical staging within four weeks of diagnosis. In progress; target 2026-02-24. **S**
- Six cycles of dostarlimab with carboplatin and paclitaxel every three weeks without a delay of more than one week. In progress; target 2026-06-30. **S**
- Lynch syndrome tumor screening completed and explained before treatment starts. In progress; target 2026-02-24. **S**
- Immune-related adverse events found early: TSH, liver tests, glucose and cortisol checked on schedule. In progress; target 2026-06-30. **S**
- PHQ-9 below 10 throughout treatment, with support she chooses. In progress; target 2026-06-30. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms (2026), National Comprehensive Cancer Network
- Updated Guidance Regarding the Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Individuals With Postmenopausal Bleeding. Obstet Gynecol 2026;148(1):e87-e91 (PMID 41990335) (2026), American College of Obstetricians and Gynecologists
- Committee Opinion No. 734: The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Women With Postmenopausal Bleeding. Obstet Gynecol 2018;131(5):e124-e129 (PMID 29683909) (2018), American College of Obstetricians and Gynecologists
- Berek JS, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet 2023;162(2):383-394 (PMID 37337978) (2023), International Federation of Gynecology and Obstetrics
- ACOG Practice Bulletin No. 147: Lynch syndrome. Obstet Gynecol 2014;124(5):1042-1054 (PMID 25437740) (2014), American College of Obstetricians and Gynecologists
- Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol 2020 (2020), American Society of Clinical Oncology
- Clarke MA, et al. Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype. JAMA Oncol 2022;8(6):895-903 (PMID 35511145) (2022), National Cancer Institute investigators (JAMA Oncology)
- Doll KM, et al. Assessment of Prediagnostic Experiences of Black Women With Endometrial Cancer in the United States. JAMA Netw Open 2020;3(5):e204954 (PMID 32412636) (2020), JAMA Network Open
- CMID: Clinical Monitoring Intelligence Database, endometrial cancer and hypothyroidism monographs (2026), Aether Forge
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Surgery in two weeks with Dr. Delacroix. Primary care review three weeks after surgery with the final pathology, the methylation and POLE results, and genetic counseling. Call for heavy bleeding, fever, or leg swelling. **S**
- Next scheduled visit 2026-02-24: review three weeks after surgical staging: final pathology and molecular class, genetic counseling, and the first cycle of dostarlimab with carboplatin and paclitaxel. **S**
